Project Grant HT94252410943

This Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $151,523 to The Medical College of Wisconsin, Inc. to investigate the role of fibrinogen in regulating inflammation and thrombus resolution in acute and chronic venous thrombosis. The research aims to develop a novel RNA therapy using lipid nanoparticles to selectively reduce circulating fibrinogen levels and elucidate its impact on thromboinflammatory processes....

This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $511,135 to the University of California, Los Angeles (UCLA) for research on the structure and biology of Tissue Factor Pathway Inhibitor-2 (TFPI-2). The key objectives of this award are to: 1) delineate the specific residues and segments of the TFPI-2 Kunitz Domain 1 (KD1) that confer protease specificity for plasmin, Factor XIa, and...

This federal Project Grant award of $499,882, provided by the National Institutes of Health (NIH) under the Trans-NIH Research Support program (CFDA 93.310), supports the development of a novel plasmin-independent thrombolytic agent for the treatment of pulmonary embolism (PE). The awardee, SNJ Pharma Inc., a minority-owned and woman-owned small business based in Torrance, CA, is evaluating the therapeutic potential of a recombinant form of the enzyme HtrA1 (rHtrA1) as a safer and more effective...

This federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $391,250.00 to Emory University to conduct research on fibrinogen as a mediator of COVID-19-associated coagulopathy. The primary objectives are to investigate the role of elevated fibrinogen levels in driving severe COVID-19 disease and explore therapeutic plasma exchange as a potential intervention. This research aims to enhance the understanding of...

This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) will fund research to investigate a novel immunocytokine therapy platform called F5111-IC for suppressing inhibitor formation in patients with hemophilia. The $1,165,276 award, effective January 1, 2025 through November 30, 2026, will support preclinical studies of this targeted immunomodulatory technology in multiple animal models of hemophilia. The principal investigator...

This $888,836 Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) to The Children's Hospital of Philadelphia (CHOP) aims to improve treatments for Hemophilia A, a genetic blood clotting disorder. The key objectives are to develop and evaluate new approaches for delivering the missing Factor VIII clotting protein to liver sinusoidal endothelial cells, which are the natural site of Factor VIII production, rather than hepatocytes...

The federal Project Grant award of $767,077 from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) seeks to validate and extend a platform technology for the delivery of protein-based thrombolytic drugs. The bioengineering strategy employs the designed assembly of endogenous biomolecules, including thrombolytic enzymes and vitamin B12, to create a biocompatible drug delivery platform that leverages the circulatory system as a natural drug depot and...

The Project Grant award of $499,585 from the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) is focused on preclinical testing and optimization of a novel therapeutic strategy to treat advanced-stage empyema, a serious pleural infection. The key products or services to be delivered under this milestone-driven, multi-principal investigator proposal include: Evaluating the efficacy of combining alteplase (a fibrinolytic agent) with a docking site peptide...

This $944,676 Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) supports the development of a novel platelet-inspired nanotechnology called Synthoplate (SP) to restore hemostasis in patients on antiplatelet agents. The technology aims to address the critical unmet need for a readily available, donor-independent therapeutic that can effectively restore hemostatic function in traumatic brain injury (TBI) patients on P2Y12...

This $558,697 federal project grant was awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) to East Carolina University (ECU). The grant, effective from September 1, 2025 to August 31, 2028, will support research to identify molecular signatures that differentiate between fibrin and its precursor fibrinogen. The goal is to enable improved clinical diagnosis and therapeutic targeting of fibrin-related pathologies. The...